Literature DB >> 31785931

Excretion of 4-fluoroamphetamine and three metabolites in urine after controlled oral ingestion.

Stefan W Toennes1, David Schneider2, Werner Pogoda2, Alexander Paulke2, Cora Wunder2, Eef L Theunissen3, Elizabeth B de Sousa Fernandes Perna3, Johannes G Ramaekers3.   

Abstract

Each year, synthetic drugs are occurring in high numbers in the illicit drug market. But data on their pharmacology and toxicology are scarcely available. Therefore, a pilot study was performed to evaluate excretion of 4-fluoroamphetamine (4FA) in humans and identify metabolites in urine. Twelve subjects ingested 100 mg and five 150 mg 4-FA in a bitter lemon drink. Urine samples were scheduled at baseline and 4 times during the following 12 h and analyzed by liquid chromatography-mass spectrometry (LC-MSMS). Concentrations of 4-FA were in the range of 0.7-38 mg/l which is in accordance with the data in previously reported cases. A marked decrease of creatinine excretion in the first two samples was noted. The creatinine normalized concentrations show a maximum 4 h after ingestion in accordance with serum pharmacokinetics. Three products of two metabolic pathways were identified in very low concentrations, two diastereomers of 4-fluorophenylpropanolamine and one ring hydroxylated 4-FA that was conjugated to a large extent. The concentration-time courses paralleled those of 4-FA. The study results show the range of 4-FA concentrations to be expected in urine after oral ingestion of typical dosages and show two pathways of 4-FA metabolism.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4-Fluoroamphetamine; Forensic toxicology; Liquid chromatography-mass spectrometry; New psychoactive substances (NPS); Pharmacokinetics; Stimulants; Urine

Mesh:

Substances:

Year:  2019        PMID: 31785931     DOI: 10.1016/j.jpba.2019.113008

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Acute onset heart failure due to reverse type Takotsubo cardiomyopathy caused by a single dose of 4-Fluoroamphetamine in a healthy young individual.

Authors:  R S D van der Pas; F M J Gresnigt; L Wansink; E J F Franssen; R K Riezebos
Journal:  Toxicol Rep       Date:  2020-12-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.